Universal Beteiligungs und Servicegesellschaft mbH Has $1.71 Million Stock Position in Embecta Corp. $EMBC

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Embecta Corp. (NASDAQ:EMBC) by 1,068.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 143,616 shares of the company’s stock after buying an additional 131,320 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Embecta were worth $1,708,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in EMBC. Jefferies Financial Group Inc. increased its holdings in Embecta by 40.4% during the third quarter. Jefferies Financial Group Inc. now owns 1,884,875 shares of the company’s stock worth $26,596,000 after buying an additional 542,162 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Embecta by 11.5% in the third quarter. Dimensional Fund Advisors LP now owns 789,509 shares of the company’s stock valued at $11,140,000 after acquiring an additional 81,218 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Embecta by 439.1% in the second quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock valued at $6,878,000 after acquiring an additional 578,174 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Embecta in the 4th quarter valued at about $5,178,000. Finally, JPMorgan Chase & Co. grew its position in shares of Embecta by 39.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 434,822 shares of the company’s stock valued at $6,135,000 after acquiring an additional 123,113 shares during the period. 93.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Embecta in a report on Friday, February 6th. Mizuho reduced their price target on Embecta from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $18.50.

Embecta Stock Performance

EMBC opened at $9.23 on Friday. The firm has a market cap of $546.60 million, a P/E ratio of 3.89 and a beta of 1.09. Embecta Corp. has a 52-week low of $8.47 and a 52-week high of $15.55. The business’s fifty day moving average is $9.26 and its 200-day moving average is $11.30.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company had revenue of $261.20 million during the quarter, compared to the consensus estimate of $258.07 million. During the same quarter in the prior year, the firm posted $0.65 EPS. The firm’s quarterly revenue was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, research analysts predict that Embecta Corp. will post 2.82 earnings per share for the current fiscal year.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.